The company's two clinical-stage technologies, GlycoConnect and HydraSpace, translate antibodies into differentiated, proprietary ADC products that can be targeted against a wide variety of cancer types.

The underlying platform ADC technology harnesses the power of the naturally-occurring glycan, present on all antibodies, as an anchor point to differentiate the efficacy and tolerability profiles of an ADC while improving manufacturability.

When combined with the toxSYN ADC payload platform, Synaffix enables any company with an existing antibody to rapidly establish a highly-competitive clinical-stage ADC program for its own development pipeline.